Table 2.
Association between clinical characteristics with EGFR mutation status
| Variable | All patients | EGFR mutation status | P | Univariate OR | |
|---|---|---|---|---|---|
| Positive | Negative | ||||
| Number of patients | 209 | 126 (60.3%) | 83 (39.7%) | NA | NA |
| Median age | 60.11 ± 9.62 | 60.22 ± 9.42 | 60.02 ± 9.79 | 0.901 | NA |
| Gender | |||||
| Female | 113 | 76 | 37 | 0.025 | Reference |
| Male | 96 | 50 | 46 | 1.890 (1.078, 3.312) | |
| Smoking history | |||||
| Yes | 49 | 16 | 33 | <0.001 | Reference |
| No | 160 | 110 | 50 | 4.537 (2.289, 8.995) | |
| Histologic subtype† | |||||
| Lepidic‡ | 38 | 23 | 15 | 0.014 | 3.833 (1.215, 12.090) |
| Acinar | 113 | 72 | 41 | 4.390 (1.581, 12.193) | |
| Papillary | 36 | 25 | 11 | 5.682 (1.741, 18.544) | |
| Solid | 21 | 6 | 15 | NA | |
| Differentiation | |||||
| High | 50 | 30 | 20 | 0.324 | 2.250 (0.563, 8.996) |
| Intermediate | 100 | 64 | 36 | 2.667 (0.706, 10.077) | |
| Low | 10 | 4 | 6 | Reference | |
| Stage | |||||
| I | 171 | 107 | 64 | 0.152 | Reference |
| II | 38 | 19 | 19 | 0.598 (0. 295, 1.213) | |
| Pathologic grade | |||||
| High | 22 | 6 | 16 | 0.003 | Reference |
| Intermediate | 149 | 97 | 52 | 4.974 (1.836, 13.480) | |
| Low | 38 | 23 | 15 | 4.089 (1.305, 12.807) | |
| Clinical symptoms | |||||
| + | 75 | 48 | 27 | Reference | |
| − | 134 | 78 | 56 | 0.412 | 1.276 (0.712, 2.287) |
| Family tumor history | |||||
| Yes | 15 | 9 | 6 | 0.981 | Reference |
| No | 194 | 117 | 77 | 1.013 (0.347, 2.960) | |
| CEA level (ng/ml) | 5.15 ± 10.64 | 3.75 ± 5.34 | 7.39 ± 15.59 | 0.021 | NA |
| CEA (ng/ml) | |||||
| ≤2.6 | 111 | 74 | 37 | 0.045 | 1.769 (1.011, 3.096) |
| >2.6 | 98 | 52 | 46 | Reference | |
†
Histologic subtype was categorized according to the 2011 International Society for Lung Cancer Research/American Thoracic Society/European Respiratory Society classification system.
‡
Histologic subtype was categorized as lepidic predominant adenocarcinoma (adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant invasive adenocarcinoma) and other subtypes of dominant histologic findings (acinar, papillary, micropapillary, and solid predominant).
CEA, carcinoembryonic antigen; CI, confidence interval; EGFR, epidermal growth factor receptor; OR, odds ratio.